SecBot SecBot
SECBOTREPLAY Home › Report › URGN

URGN · UroGen reported Q2 2026 revenue of $72.5M (consensus $63.5M, +14.2%…

UroGen Pharma Ltd. · 8-K filed Aug 5, 2026 at 08:02 ET

At the news

BULLISHIMPACT 7/10

8-K filed Aug 5, 2026 at 08:02 ET

UroGen reported Q2 2026 revenue of $72.5M (consensus $63.5M, +14.2% beat), driven by ZUSDURI's $50.4M in revenue (73% QoQ growth). EPS of -$0.28 was a 5.7% miss vs consensus -$0.27. The company raised FY2026 operating expense guidance to $260M-$270M to accelerate ZUSDURI commercialization and pipeline investment. ZUSDURI's accelerating launch trajectory and a new patent allowance extending protection to 2044 are strong positives, but the EPS miss and rising spend temper the outlook.

  • Total revenue $72.5M in Q2 2026, up 199% YoY from $24.2M
  • ZUSDURI revenue $50.4M, 73% QoQ growth from Q1 2026
  • EPS -$0.28 vs consensus -$0.27 (5.7% miss)
  • FY2026 operating expense guidance raised to $260M-$270M from $240M-$250M

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access